RareCyte, Inc.
Eric Kaldjian, MD, SVP Clinical Research at RareCyte, has more than 25 years of industry research and development experience in liquid biopsy and spatial biology; pharmaceutical discovery, non-clinical development, and early through late-stage clinical development; companion diagnostics; cell therapy; molecular diagnostics; and genomics. He is a board-certified pathologist with specific domain expertise in oncology and immunology, more than 40 peer-reviewed research publications. Dr. Kaldjian earned his MD and trained in pathology at the University of Michigan and was a research fellow at the National Cancer Institute. After nine years at RareCyte as Chief Medical Officer, his current focus is on clinical research. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. His pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has a degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.